

FILE 'REGISTRY' ENTERED AT 21:19:54 ON 09 AUG 2002

L1 1 S ELLAGIC ACID/CN
L2 0 S TANNIN/CN
L3 38 S TANNIN
L4 0 S TANNIC ACID/CN
L5 0 S REINOID/CN
L6 1 S RETIN A/CN
L7 2 S VITAMIN A/CN

FILE 'CAPLUS, BIOSIS, EMBASE, USPATFULL' ENTERED AT 21:21:54 ON 09 AUG 2002

L8 3776 S L1 OR (ELLAGIC ACID) OR (BENZOARIC ACID) OR (ELEAGIC ACID)
OR
L9 196094 S L6 OR L7 OR RETINOID# OR (RETINOIC ACID) OR RETINO##### OR
(V
L10 9 S L8 (20W) L9
L11 7 DUPLICATE REMOVE L10 (2 DUPLICATES REMOVED)
L12 127 S L8 AND L9
L13 5 S L12 AND AFRICANUM
L14 5 S L12 AND PYGEUM
L15 0 S L13 NOT L14

L5 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2003:472982 CAPLUS

DOCUMENT NUMBER: 139:57925

TITLE: Topical compositions containing enzymes and salts for
improvement of skin barrier function and
cohesion

INVENTOR(S): Elias, Peter M.; Feingold, Kenneth R.; Fluhr, Joachim
W.; Mauro, Theodora M.; Behne, Martin J.

PATENT ASSIGNEE(S): The Regents of the University of California, USA

SOURCE: U.S. Pat. Appl. Publ., 14 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003113312	A1	20030619	US 2001-17038	20011214
WO 2003051296	A2	20030626	WO 2002-US39533	20021209
WO 2003051296	A3	20040115		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-17038 A 20011214

TI Topical compositions containing enzymes and salts for **improvement**
of skin barrier function and **cohesion**

IT Mucous membrane
(disorder; topical compns. contg. enzymes and salts for
improvement of skin barrier function and **cohesion**)

IT Skin
(**epidermis**, disorder; topical compns. contg. enzymes and
salts for **improvement** of skin barrier function and
cohesion)

IT Skin
(stratum corneum; topical compns. contg. enzymes and salts for
improvement of skin barrier function and **cohesion**)

IT Buffers
Skin
Skin, disease
(topical compns. contg. enzymes and salts for **improvement** of
skin barrier function and **cohesion**)

IT Enzymes, biological studies
Phospholipids, biological studies
Salts, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. contg. enzymes and salts for **improvement** of
skin barrier function and **cohesion**)

IT Drug delivery systems

(topical; topical compns. contg. enzymes and salts for
improvement of skin barrier function and **cohesion**)

IT 71-52-3, Bicarbonate, biological studies 77-92-9, biological studies
506-87-6, Ammonium carbonate 631-61-8, Ammonium acetate 1132-61-2,
MOPS 2644-64-6, Dipalmitoylphosphatidylcholine 4432-31-9, MES
5625-37-6, 1,4-Piperazinediethanesulfonic acid 6484-52-2, Ammonium
nitrate, biological studies 7365-44-8, TES 7365-45-9, HEPES
7632-50-0, Ammonium citrate 7783-20-2, Ammonium sulfate, biological
studies 9001-84-7, Phospholipase A2 9013-93-8, Phospholipase
9043-29-2, Phospholipase A1 10124-31-9, Ammonium phosphate
12027-06-4,
Ammonium iodide 12124-97-9, Ammonium bromide 12125-01-8, Ammonium
fluoride 12125-02-9, Ammonium chloride, biological studies
14265-44-2,
Phosphate, biological studies 14307-43-8, Ammonium tartrate
17026-44-7, Ammonium sulfonate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. contg. enzymes and salts for **improvement** of
skin barrier function and **cohesion**)

IT 544724-10-9 544724-11-0
RL: PRP (Properties)
(unclaimed sequence; topical compns. contg. enzymes and salts for
improvement of skin barrier function and **cohesion**)

L5 ANSWER 2 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:3130 USPATFULL

TITLE: Use of dictyotal extracts in the production of a
topical composition

INVENTOR(S): Gutierrez, Gilles, Lyon, FRANCE
Serrar, Mostafa, Saint Bonnet De Mure, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003003164	A1	20030102
APPLICATION INFO.:	US 2001-914823	A1	20011005 (9)
	WO 2001-FR67		20010110

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2000-238	20000110
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BIERMAN MUSERLIAN AND LUCAS, 600 THIRD AVENUE, NEW YORK, NY, 10016	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	381	

SUMM . . . CK1 and CK10, and the increase of desmosomial proteins to
contribute to the consolidation of the stratified structure of the
epidermis.

SUMM [0005] The **epidermis** which represents the surface section of
the skin is formed from a succession of several layers of keratinocytes
that are. . .

SUMM [0007] This stratified structure of the suprabasal layers of the
epidermis can be modulated by several factors and particularly
by soluble or ionic calcium--as opposed to fixed calcium: in the
presence. . .

SUMM [0013] The maturation of keratinocytes results at tissue level in an **improvement** in the attachment and **cohesion** of the cells, linked with an increase in the expression of desmosomial proteins. The maturation of Keratinocytes is very active. . .

L5 ANSWER 3 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:129693 USPATFULL
TITLE: Comixture of dextran sulfate/escin for treating skin redness/edema and/or sensitive skin
INVENTOR(S): Renault, Beatrice, Saint Maurice, FRANCE
PATENT ASSIGNEE(S): Societe L'Oreal S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6562355	B1	20030513
APPLICATION INFO.:	US 2000-684986		20001010 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1999-12589	19991008
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Tran, S.	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	627	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . but also by bags and/or dark rings and/or edema, of more persistent discomfort reflecting a greater metabolic depletion of the **epidermis** and the dermis.

SUMM . . . blood circulation (EP-158,090 and U.S. Pat. No. 4,983,626), in compositions for treating the skin such as anti-inflammatory agents (EP-728,472), for **improving** the **cohesion** between the dermis and the **epidermis** (WO-98/19664) and in skin-lightening cosmetic compositions (JP-07,076,512).

L5 ANSWER 4 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2003:81467 USPATFULL
TITLE: Transdermal therapeutic system containing the active substance scopolamine base
INVENTOR(S): Muller, Walter, Neuwied, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme AG, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6537571	B1	20030325
	WO 9911265		19990311
APPLICATION INFO.:	US 2000-485912		20000404 (9)
	WO 1998-EP5224		19980818

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19738643	19970904

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Ghali, Isis
LEGAL REPRESENTATIVE: Hochberg, D. Peter, Vieyra, Katherine R., Mellino, Sean
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 270

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . example. Other additives, such as, for example, silica gels having a high specific surface, may be used in order to **improve** the physical properties of the adhesive coatings, for example their **cohesion**.

DETD . . . produced according to Examples 1 to 3. For determination of the values so-called Franz' diffusion cells were employed, using human **epidermis**. The results show that the permeation profiles of the systems according to the invention are almost identical with those of.
. . .

L5 ANSWER 5 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2002:185305 USPATFULL
TITLE: USE OF ELLAGIC ACID AND ITS DERIVATIVES IN COSMETICS AND DERMATOLOGY
INVENTOR(S): BONTE, FREDERIC, ORLEANS, FRANCE
SAUNOIS, ALEX, ORLEANS, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098213	A1	20020725
APPLICATION INFO.:	US 2000-508670	A1	20000328 (9)
	WO 1998-FR2098		19981001

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1997-12227	19971001
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DENNISON, SCHULTZ & DOUGHERTY, 1745 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	602	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . referred to as collagen VII, is the predominant constituent of the anchoring fibrils associated with the basal membrane joining the **epidermis** to the dermis. It is synthesized by the keratinocytes of the basal layer of the **epidermis** and to a lesser extent by the fibroblasts of the dermis, as described by R. Burgeson in the publication entitled. . .

SUMM . . . (1994) 102, 205-209), certain manifestations of skin ageing, such as increased delicacy of the skin and reduced ability of the **epidermis** to repair itself, might be attributable to a decrease in the synthesis of collagen VII in elderly subjects. It will. . .

SUMM [0011] Finally, it is also known that the dermis-**epidermis** cohesion is of prime importance for the basal populations of the

epidermal keratinocytes to have an optimum metabolism, a good. . . good-quality, elastic and well-formed corneal layer with optimum internal hydration which respects the functionalities of the cellular layers. A good dermis-**epidermis** cohesion thus participates in the formation and maintenance of skin at metabolic equilibrium, giving it especially a good esthetic appearance.

DETD . . . of collagen VII, particularly with a view on the one hand to favoring the cohesion between the dermis and the **epidermis**, and on the other hand, at the level of the hair follicles of the scalp, to contributing towards the restoration. . . .

DETD [0014] Such compositions make it possible in particular to favor the cohesion between the dermis and the **epidermis** in persons whose skin is atonic or loose. They can also be useful in hair care for improving hair condition,. . . .

DETD . . . its salts, its metal complexes or its mono- or polyether or mono- or poly-acylated derivatives as a cosmetic agent for **improving** the **cohesion** between the dermis and the **epidermis**, said agent preferably being incorporated into a cosmetic composition comprising a cosmetically acceptable vehicle.

DETD [0016] Advantageously, the **improvement** in the **cohesion** between the dermis and the **epidermis** is realized by reinforcing the dermal-epidermal junction.

DETD [0019] Thus the compositions of the invention prove particularly useful in all applications where it is desired to **improve** the **cohesion** between the dermis and the **epidermis**.

DETD . . . composition, especially dermatological composition, for treating pathological conditions associated with a deficiency in the cohesion between the dermis and the **epidermis**, particularly conditions associated with a weakening of the dermal-epidermal junction,

such as epidermolysis bullosa, or for treating manifestations or pathological. . . .

DETD [0034] The invention further relates in particular to a method of cosmetic treatment for **improving** the **cohesion** between the dermis and the **epidermis**, particularly by reinforcing the dermal-epidermal junction, for toning up the skin, for preventing or delaying the appearance of signs of. . . .

DETD . . . and its derivatives according to the invention can advantageously be used as agents for reinforcing the dermal-epidermal junction and thereby **improving** the **cohesion** between the dermis and the **epidermis**. Ellagic acid and its derivatives according to the invention can therefore advantageously be used in cosmetic "antiwrinkle", "anti-ageing" and "toning". . . .

CLM What is claimed is:

. . . its salts, its metal complexes or its mono- or polyether or mono- or polyacylated derivatives as a cosmetic agent for **improving** the **cohesion** between the dermis and the **epidermis**, said agent being incorporated into a cosmetic composition comprising a cosmetically acceptable vehicle.

. . . composition, especially dermatological composition, for treating pathological conditions associated with a deficiency in the cohesion between the dermis and the **epidermis**, particularly conditions associated with a weakening of the dermal-epidermal junction.

16. Method of cosmetic treatment for **improving** the **cohesion** between the dermis and the **epidermis**, particularly by reinforcing the dermal-epidermal junction, for toning

up

the skin, for preventing or delaying the appearance of signs of. . .

L5 ANSWER 6 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2001:71121 USPATFULL
TITLE: Composition for controlled and sustained transdermal administration
INVENTOR(S): Carrara, Dario, Buenos Aires, Argentina
PATENT ASSIGNEE(S): Permateg Technologie AG, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6231885	B1	20010515
APPLICATION INFO.:	US 1998-153798		19980915 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1997-MI2106	19970917
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Clardy, S. Mark	
ASSISTANT EXAMINER:	Williamson, Michael A.	
LEGAL REPRESENTATIVE:	Hedman & Costigan, PC	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 14 Drawing Page(s)	
LINE COUNT:	1654	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . systemic concentration. This formulation contains defined amounts of chemicals that minimize the barrier characteristics of the uppermost layer of the **epidermis** and provide sustained and controlled permeation rate. Said chemicals are: fatty acids such as oleic acid, palmitoleic acid, palmitic acid, . . .

DETD . . . comprises from 5.0 to 25.0% (w/w), preferably 7.0 to 15.0% (w/w) and most preferably 10.0% (w/w). Ethylcellulose, is used for **improving** and balancing the adhesive properties (adhesion and **cohesion**) is comprised from 0.1 to 5.0% (w/w), preferably 0.1 to 1.5% (w/w), and most preferably 0.3% (w/w). BHT and BHA. . .

L5 ANSWER 7 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2001:29129 USPATFULL
TITLE: Use of potentilla erecta extract in the cosmetic and pharmaceutical field
INVENTOR(S): Bonte, Frederic, Orleans, France
Dumas, Marc, Orleans, France
Chaudagne, Catherine, Vitry-Aux-Loges, France
Meybeck, Alain, Courbevoie, France
PATENT ASSIGNEE(S): LVMH Recherche, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6193975	B1	20010227
	WO 9819664		19980514
APPLICATION INFO.:	US 1999-297679		19990506 (9)
	WO 1997-FR1988		19971106
			19990506 PCT 371 date
			19990506 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1996-13585	19961107
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Prats, Francisco	
ASSISTANT EXAMINER:	Coe, Susan D.	
LEGAL REPRESENTATIVE:	Nath & Associates, Nath, Gary M.	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	639	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . as collagen VII, is the main constituent of the anchoring fibrils which are combined with the basal membrane, linking the **epidermis** to the dermis. It is synthesised by the keratinocytes of the basal layer of the **epidermis**, and in a lesser amount, by the fibroblasts of the dermis, as described by R.Burgeson in a publication entitled: "Type. . .

SUMM . . . manifestations of skin ageing, such as an increased skin fragility and a decrease in the capacities of repair of the **epidermis**, might be attributable to a reduction of the synthesis of collagen VII in aged subjects. It will be noted that. . .

SUMM . . . preparation of topical cosmetic or dermatological compositions.

Such compositions in particular enable promoting the cohesion between the dermis and the **epidermis** in persons having a loosened or dull skin. The compositions have also proved to be useful for hair

cares

which. . .

SUMM . . . characteristics, the invention relates to the use of an extract

of the plant *Potentilla erecta* as cosmetic agent intended for **improving** the **cohesion** between the dermis and the **epidermis** by reinforcing the dermo-epidermal junction, said agent being incorporated in a cosmetic composition comprising a cosmetically acceptable vehicle.

SUMM Thus, the compositions of the invention prove to be particularly useful in any application in which it is sought to **improve** the **cohesion** between the dermis and the **epidermis**.

SUMM . . . notably a dermatological composition, intended for treating pathologies linked to a deficiency in the cohesion between the dermis and the **epidermis**, in particular those linked to a weakening of the dermo-epidermal junction.

SUMM . . . dermatological treatment, according to which it is sought to obtain an improvement of the junction between the dermis and the **epidermis**, by a reinforcement of the dermo-epidermal junction, or a stimulation of the synthesis of collagen VII.

DETD . . . anchoring fibrils, these extracts can therefore advantageously be used as an agent for reinforcing the dermo-epidermal junction, and for thus **improving** the **cohesion** between the dermis and the **epidermis**.

CLM What is claimed is:

. . . the human body selected from the group consisting of a method for improving the junction between the dermis and the **epidermis** by reinforcement of the dermo-epidermal junction and a method for stimulating the formation of collagen VII, which comprises the topical.

. . . the human body selected from the group consisting of a method for improving the junction between the dermis and the **epidermis** by a reinforcement of the dermo-epidermal junction, and a method for stimulating the formation of collagen VII, which comprises the. . .
 23. A method of cosmetic care for improving the junction between the dermis and the **epidermis** by the reinforcement of the dermo-epidermal junction, comprising the topical application to an external area of the human body of a cosmetical or pharmaceutical composition comprising as sole agent for improving the junction between the dermis and the **epidermis**, an effective amount of an extract of the plant *Potentilla erecta*, said extract being obtained by extraction with the aid. . .

L5 ANSWER 8 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2000:34208 USPATFULL
 TITLE: Lipophilic hydroxylated acid, its use in cosmetics and pharmacy, and its process of preparation
 INVENTOR(S): Perrier, Eric, Vienne, France
 Antoni, Daniele, Vernaison, France
 Huc, Alain, Sainte fdy les Lyon, France
 PATENT ASSIGNEE(S): Coletica, Lyons, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6039961		20000321
APPLICATION INFO.:	US 1998-66587		19980427 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-557154, filed on 16 Feb 1996, now patented, Pat. No. US 5869069 which is a continuation-in-part of Ser. No. US 354228		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1994-9091	19940722
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Armstrong, Westerman, Hattori, McLeland and Naughton	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1382	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . or under the action of skin or bacterial enzymes. In addition, their affinity with respect to lipid constituents of the **epidermis** remains limited.

SUMM . . . be used as cosmetic or pharmaceutical and/or dermatological products having a greater affinity with respect to lipid constituents of

the **epidermis**, in particular the stratum corneum, which are non-irritant and which have a modifiable effectiveness.

SUMM . . . to solve the new technical problem consisting in providing a solution which makes it possible to produce new agents which **improve** skin moisturizing, elasticity and **cohesion** as well as new depigmenting agents, without significant irritant power.

SUMM . . . makes it possible to improve the subsequent enetration by other

active ingredients, a stimulating activity of the cell functions, which **improves** the elasticity and the **cohesion** of the skin,

a depigmenting activity, an anti-wrinkle or anti-age activity, a moisturizing activity which makes it possible to treat. . . .
 SUMM . . . method, for cosmetic or therapeutic use, for chemical exfoliation of the skin, for stimulating the cells of the skin, for **improving** the elasticity and the **cohesion** of the skin, for depigmenting the skin, for moisturizing the skin, or for producing an anti-wrinkle effect on the skin, . . .

L5 ANSWER 9 OF 16 USPATFULL on STN

ACCESSION NUMBER: 1999:166609 USPATFULL
 TITLE: Cosmetic or pharmaceutical, particularly dermatological, composition containing a Bertholletia extract
 INVENTOR(S): Bonte, Frederic, Orleans, France
 Dumas, Marc, Orleans, France
 Lavaud, Catherine, Tingueux, France
 Massiot, Georges, Reims, France
 PATENT ASSIGNEE(S): LVMH Recherche, Nanterre, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6004568		19991221
APPLICATION INFO.:	US 1997-917622		19970811 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1996-FR256, filed on 16 Feb 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1996-10356	19960822
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Clardy, S. Mark	
ASSISTANT EXAMINER:	Williamson, Michael A.	
LEGAL REPRESENTATIVE:	Dennison, Meserole, Scheiner & Schultz	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1039	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM Type VII collagen is the predominant constituent of the anchoring fibrils, associated with the basement membrane, connecting the **epidermis** to the dermis. It is synthesized by the basal keratinocytes and, to a lesser extent, by the fibroblasts of the. . . .
 SUMM . . . manifestations of skin ageing, such as an increase in skin fragility and a decrease in the repair capabilities of the **epidermis**, might be attributable to a reduction in collagen VII synthesis in the elderly.
 SUMM . . . composition, which is effective in preventing or treating the effects of skin ageing and in firming the skin, or for **improving** healing, for **improving** the dermal-epidermal **cohesion**, or which is effective against free radicals or for promoting incorporation of vitamin C by skin cells.
 SUMM . . . is to promote collagen VII synthesis, the composition will prove particularly useful in all applications where it is desired to **improve** the epidermal-dermal **cohesion**. This may involve in particular an anti-wrinkle product or a product for combating actinic ageing of the skin, i.e. ageing. . . .

DETD . . . is therefore to strengthen the structure and properties of the epidermal-dermal junction, an exchange zone between the dermis and the **epidermis** and a very important zone for the keratinocyte differentiation processes.

L5 ANSWER 10 OF 16 USPATFULL on STN

ACCESSION NUMBER: 1999:18741 USPATFULL
TITLE: Lipophilic hydroxylated acid, its use in cosmetics and pharmacy, and its process of preparation
INVENTOR(S): Perrier, Eric, Vienne, France
Antoni, Daniele, Vernaison, France
Huc, Alain, Sainte FDY les Lyon, France
PATENT ASSIGNEE(S): Coletica, Lyons, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869069		19990209
	WO 9603110		19960208
APPLICATION INFO.:	US 1996-557154		19960216 (8)
	WO 1995-FR984		19950721
			19960216 PCT 371 date
			19960216 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-354228, filed on 12 Dec 1994, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1994-9091	19940722
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Armstrong, Westerman, Hattori, McLeland & Naughton	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1331	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . or under the action of skin or bacterial enzymes. In addition, their affinity with respect to lipid constituents of the **epidermis** remains limited.

SUMM . . . be used as cosmetic or pharmaceutical and/or dermatological products having a greater affinity with respect to lipid constituents of

the **epidermis**, in particular the stratum corneum, which are non-irritant and which have a modifiable effectiveness.

SUMM . . . to solve the new technical problem consisting in providing a solution which makes it possible to produce new agents which **improve** skin moisturizing, elasticity and **cohesion** as well as new depigmenting agents, without significant irritant power.

SUMM . . . makes it possible to improve the subsequent penetration by other active ingredients, a stimulating activity of the cell functions, which **improves** the elasticity and the **cohesion** of the skin, a depigmenting activity, an anti-wrinkle or anti-age activity,

SUMM . . . a moisturizing activity which makes it possible to treat. . . .
method, for cosmetic or therapeutic use, for chemical exfoliation of the skin, for stimulating the cells of the skin, for **improving** the elasticity and the **cohesion** of the skin,

for depigmenting the skin, for moisturizing the skin, or for producing an anti-wrinkle effect on the skin, . . .

CLM What is claimed is:

. . . activity is a treatment selected from the group consisting of a treatment for stimulating the skin cells, a treatment for **improving** the elasticity and the **cohesion** of the skin, a method for depigmenting the skin and a method for performing an anti-wrinkle effect of the skin.

. . .

L5 ANSWER 11 OF 16 USPATFULL on STN

ACCESSION NUMBER: 1998:28112 USPATFULL

TITLE: N-acyl-ethylene triacetic composition for treating abnormal keratinization

INVENTOR(S): Ptchelintsev, Dmitri, Mahwah, NJ, United States

PATENT ASSIGNEE(S): Avon Products, Inc., Suffern, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5728733		19980317
APPLICATION INFO.:	US 1996-762716		19961210 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-549419, filed on 27 Oct 1995, now patented, Pat. No. US 5621008		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Cook, Rebecca		
LEGAL REPRESENTATIVE:	Hopgood, Calimafde, Kalil & Judlowe, LLP		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
LINE COUNT:	402		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM Abnormal keratinization is associated with the stratum corneum layer of the **epidermis**. The stratum corneum layer is composed of clear, dead squamous epithelial cells called corneocytes. Abnormal keratinization often appears as areas. . .

SUMM . . . magnification. Whatever the ideology, the buildup of keratin is

often undesirable, and a need exists in the art for an **improved** method of decreasing **cohesion** of corneocytes and promoting exfoliation of the cornified layers from the stratum corneum.

L5 ANSWER 12 OF 16 USPATFULL on STN

ACCESSION NUMBER: 97:93890 USPATFULL

TITLE: Use of a simaba extract to reduce patchy skin pigmentation, enhance the protective function of the skin or prepare a skin cell culture medium and resulting composition

INVENTOR(S): Bonte, Frederic, Courbevoie, France
Meybeck, Alain, Courbevoie, France
Dumas, Marc, Colombes, France

PATENT ASSIGNEE(S): LVMH Recherche, Nanterre, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5676949		19971014
	WO 9413259		19940623

APPLICATION INFO.: US 1995-448563 19950801 (8)
 WO 1993-FR1224 19931210
 19950801 PCT 371 date
 19950801 PCT 102(e) date

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	FR 1992-14969	19921211
	FR 1993-9493	19930802
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dodson, Shelley A.	
LEGAL REPRESENTATIVE:	Larson and Taylor	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
LINE COUNT:	847	
SUMM	<p>. . . in promoting keratinocyte differentiation and can thus be used for treating skin disorders accompanied by keratinocyte differentiation disorder. In the epidermis, this differentiation manifests itself in particular by a greater cell cohesion, by a regulation of the transformation of keratinocytes to. . . the skin against the external environment and to enhancement of the water barrier, which prevents excessive water loss through the epidermis; in the hair follicle, this differentiation manifests itself by a regulation of the processes of keratin synthesis by the keratinocytes,. . .</p>	
SUMM	<p>. . . skin, especially the water barrier function, thereby producing a moisturizing effect, in particular by preventing excessive water loss through the epidermis, an advantageous application of which is the treatment of ichthyotic skin and the treatment of psoriatic skin, and improving the. . .</p>	
SUMM	<p>. . . water barrier function, thereby making it possible especially to obtain a moisturizing effect by preventing excessive water loss through the epidermis, hence permitting use especially for the treatment of dry skin irrespective of the degree of dryness, including ichthyotic skin and. . .</p>	
SUMM	<p>. . . skin or scalp to be treated, is to regulate the keratinocyte differentiation, thereby promoting the formation and restoration of an epidermis of good quality, especially in the stratum corneum, enhance the barrier function of the skin which protects the epidermis, in particular the water barrier function, and make the hair more attractive, as explained above in the context of the. . .</p>	
SUMM	<p>. . . cosmetic or dermatological composition according to the invention has a moisturizing capacity, especially by preventing excessive water loss through the epidermis, and can be intended for the treatment of dry skin, especially ichthyotic skin.</p>	
DETD	<p>compositions promoting the formation of a well-differentiated epidermis, i.e. giving a "beautiful" skin with a pleasant texture and feel;</p>	
DETD	<p>. . . from external aggression, for example by allergens or surfactants, on the one hand, and limiting excessive water loss through the epidermis, on the other;</p>	
DETD	<p>Cosmetic composition for maintaining a satisfactory state of hydration of the epidermis</p>	
DETD	<p>. . . to the legs after depilation. This composition makes it possible in particular to enhance the water barrier function of the epidermis by improving the epidermal intercellular</p>	

cohesion. It thus enables the skin to preserve a satisfactory state of hydration.

DETD Liposomal cosmetic composition for rebalancing the desquamation of the stratum corneum of the **epidermis** and restoring a smooth **epidermis**

DETD . . . lipids, which are sources of starting material for the formulation of cosmetic or pharmaceutical compositions for topical application to the **epidermis** or scalp.

CLM What is claimed is:

. . . need of treatment selected from the group consisting of depigmentation, promoting keratinocyte differentiation, preserving or enhancing protective function of skin, **improving cohesion** of epidermal cells and improving the quality of hair, comprising delivering to said body areas an amount of a simaba. . .

L5 ANSWER 13 OF 16 USPATFULL on STN

ACCESSION NUMBER: 97:93889 USPATFULL

TITLE: Use of a simarouba extract for reducing patchy skin pigmentation

INVENTOR(S): Bonte, Frederic, Courbevoie, France
Meybeck, Alain, Courbevoie, France
Dumas, Marc, Colombes, France

PATENT ASSIGNEE(S): LVMH Recherche, Nanterre, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5676948		19971014
	WO 9413260		19940623
APPLICATION INFO.:	US 1995-448562		19950801 (8)
	WO 1993-FR1225		19931210
			19950801 PCT 371 date
			19950801 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1992-14968	19921211
	FR 1993-9492	19930802
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dodson, Shelley A.	
LEGAL REPRESENTATIVE:	Larson and Taylor	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
LINE COUNT:	841	

SUMM . . . in promoting keratinocyte differentiation and can thus be used for treating skin disorders accompanied by keratinocyte differentiation disorder. In the **epidermis**, this differentiation manifests itself in particular by a greater cell cohesion, by a regulation of the transformation of keratinocytes to. . . the skin against the external environment and to enhancement of the water barrier, which prevents excessive water loss through the **epidermis**; in the hair follicle, this differentiation manifests itself by a regulation of the processes of keratin synthesis by the keratinocytes, . . .

SUMM . . . skin, especially the water barrier function, thereby producing a moisturizing effect, in particular by preventing excessive water loss through the **epidermis**, an advantageous application of which is

the treatment of ichthyotic skin and the treatment of psoriatic skin, and improving the. . .

SUMM . . . water barrier function, thereby making it possible especially to obtain a moisturizing effect by preventing excessive water loss through the **epidermis**, hence permitting use especially for the treatment of dry skin irrespective of the degree of dryness, including ichthyotic skin and. . .

SUMM . . . skin or scalp to be treated, is to regulate the keratinocyte differentiation, thereby promoting the formation and restoration of an **epidermis** of good quality, especially in the stratum corneum, enhance the barrier function of the skin which protects the **epidermis**, in particular the water barrier function, and make the hair more attractive, as explained above in the context of the. .

SUMM . . . cosmetic or dermatological composition according to the invention has a moisturizing capacity, especially by preventing excessive water loss through the **epidermis**, and can be intended for the treatment of dry skin, especially ichthyotic skin.

DETD compositions promoting the formation of a well-differentiated **epidermis**, i.e. giving a "beautiful" skin with a pleasant texture and feel;

DETD . . . from external aggression, for example by allergens or surfactants, on the one hand, and limiting excessive water loss through the **epidermis**, on the other;

DETD Cosmetic composition for maintaining a satisfactory state of hydration of the **epidermis**

DETD . . . to the legs after depilation. This composition makes it possible in particular to enhance the water barrier function of the **epidermis** by **improving** the epidermal intercellular **cohesion**. It thus enables the skin to preserve a satisfactory state of hydration.

DETD Liposomal cosmetic composition for rebalancing the desquamation of the stratum corneum of the **epidermis** and restoring a smooth **epidermis**

DETD . . . lipids, which are sources of starting material for the formulation of cosmetic or pharmaceutical compositions for topical application to the **epidermis** or scalp.

CLM What is claimed is:

. . . need of treatment selected from the group consisting of depigmentation, promoting keratinocyte differentiation, preserving or enhancing protective function of skin, **improving cohesion** of epidermal cells and improving the quality of hair, comprising delivering to said body areas an amount of a simarouba. .

L5 ANSWER 14 OF 16 USPATFULL on STN

ACCESSION NUMBER: 97:31730 USPATFULL

TITLE: N-acyl-ethylene-triacetic acids

INVENTOR(S): Ptchelintsev, Dmitri, Mahwah, NJ, United States

PATENT ASSIGNEE(S): Avon Products, Inc., Suffern, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5621008		19970415
APPLICATION INFO.:	US 1995-549419		19951027 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

PRIMARY EXAMINER: Cook, Rebecca
LEGAL REPRESENTATIVE: Hopgood, Calimafde, Kalil & Judlowe
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 427

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM Abnormal keratinization is associated with the stratum corneum layer of the **epidermis**. The stratum corneum layer is composed of clear, dead squamous epithelial cells called corneocytes. Abnormal keratinization often appears as areas. . .

SUMM . . . magnification. Whatever the ideology, the buildup of keratin is

often undesirable, and a need exists in the art for an **improved** method of decreasing **cohesion** of corneocytes and promoting exfoliation of the cornified layers from the stratum corneum.

L5 ANSWER 15 OF 16 USPATFULL on STN

ACCESSION NUMBER: 97:20247 USPATFULL

TITLE: Use of an ecdysteroid for the preparation of cosmetic or dermatological compositions intended, in particular,

for strengthening the water barrier function of the skin or for the preparation of a skin cell culture medium, as well as to the compositions

INVENTOR(S): Meybeck, Alain, Courbevoie, France
Bonte, Fr ed eric, Courbevoie, France
Redziniak, G erard, Saint Cyr En Val, France
PATENT ASSIGNEE(S): LVMH Recherche, Nanterre, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5609873		19970311
	WO 9404132		19940303
APPLICATION INFO.:	US 1995-393009		19950427 (8)
	WO 1993-FR819		19930820
			19950427 PCT 371 date
			19950427 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1992-10267	19920825
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rollins, John W.	
LEGAL REPRESENTATIVE:	Lowe, Price, LeBlanc & Becker	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	792	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . softer appearance, to strengthen the water barrier function of skin, and to strengthen the cohesion of the cells of the **epidermis**. This composition may also be used for improving the hair appearance. The cell medium may be used advantageously for the. .

SUMM . . . the skin with respect to the external environment and to strengthen the water barrier preventing excessive water loss through the

epidermis; and, at hair follicle level, to regulate or even increase the synthesis by keratinocytes of keratin, the main constituent of. . .

SUMM . . . accompanied by a disturbance of keratinocyte differentiation, such as psoriasis, for restoring, preserving and/or strengthening the protective function of the **epidermis**, in particular through improvement or strengthening of the cornified layer and the water barrier function, thus leading to a hydrating effect, especially by preventing excessive water loss through the **epidermis**, an advantageous application of which is the treatment of ichthyotic skins as well as the treatment of psoriatic skins, and. . .

SUMM . . . strengthening of the cornified layer and the water barrier function, as well as the cohesion of the cells of the **epidermis**, or alternatively for improving the quality of hair in terms of its constitution; or for the preparation of a cell. . .

SUMM . . . to be treated, have the effect of regulating keratinocyte differentiation, thereby promoting the formation or restoration of a good quality **epidermis**, in particular in respect of the cornified layer, especially as regards its composition and its structural organization. This enables the **epidermis**, on the one hand, in particular through a strengthened cellular cohesion, to possess properties of optimal protection with respect to surrounding environments, and on the other hand to treat disorders of the **epidermis** accompanied by a disturbance of keratinocyte differentiation.

SUMM . . . to the invention make it possible, in particular, to restore, preserve and strengthen the protective skin barrier function of the **epidermis**, especially the water barrier function, and thereby to obtain, in particular, a hydrating effect by preventing excessive water loss through the **epidermis**. The compositions according to the invention may hence be advantageously used for the treatment of dry skins, irrespective of the. . .

SUMM . . . improvement of the cornified layer and the water barrier function, as well as the cohesion of the cells of the **epidermis**, or alternatively for improving the quality of hair in terms of its constitution, characterized in that it contains as active. . .

SUMM . . . or dermatological composition according to the invention displays a hydrating power, in particular by preventing excessive water loss through the **epidermis**, and can be intended for the treatment of dry skins, in particular ichthyotic skins.

DETD the . . . keratinocyte differentiation, the compositions according to the invention containing an ecdysteroid, as defined above, enable a good state of the **epidermis** of "normal" skin to be maintained, in particular by maintaining its suppleness and its functional role, especially its protective barrier. . .

DETD . . . case of dry skins, especially ichthyosis, keratinocyte differentiation is imperfect, accompanied by malformation of the keratohyalin granules and desmosomes. The **epidermis** displays an abnormal keratinization, leading to a disturbance of the barrier, in particular water barrier, properties, and a loss of. . .

DETD Dermatological composition for restoring the water barrier of the **epidermis**

DETD Cosmetic composition for maintaining a satisfactory state of hydration of the **epidermis**

DETD . . . the legs after depilation. This composition makes it possible, in particular, to strengthen the cutaneous water barrier function of the

epidermis by **improving** epidermal intercellular **cohesion**. It thus enables the skin to retain a satisfactory state of hydration.

DETD Liposomal cosmetic composition for re-equilibrating the desquamation of the cornified layer of the **epidermis**, and restoring smoothness to the **epidermis**

DETD . . . cohesion of the cornified layer, and normalizes the detachment of dead cells, thereby giving them the appearance of a smoother **epidermis**.

DETD . . . mainly containing lipids, sources of starting materials for the

formulation of cosmetic or pharmaceutical compositions for topical application to the **epidermis** or scalp, are recovered.

CLM What is claimed is:

1. A method of treatment selected from the group consisting of promoting the cohesion of the cells of the **epidermis**, promoting keratynocyte differentiation and improving the quality of hair constitution, comprising administering to zones of the skin and scalp in. . .

L5 ANSWER 16 OF 16 USPATFULL on STN

ACCESSION NUMBER: 93:87119 USPATFULL

TITLE: Skin cream composition

INVENTOR(S): Mausner, Jack, New York, NY, United States

PATENT ASSIGNEE(S): Chanel, Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5254331		19931019
APPLICATION INFO.:	US 1991-758768		19910912 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ore, Dale E.		
LEGAL REPRESENTATIVE:	Farber, Michael B.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
LINE COUNT:	849		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



DETD . . . to stimulate the regeneration of epidermal cells and stimulate the activity of fibroblasts to produce a thickening effect of the **epidermis** similar to that seen with retinoic acid. This effect is believed to be responsible for making the skin more elastic, . . .

DETD . . . have a powerful hydrating effect, together with the ability to restructure and reinforce the barrier effect of the skin and **improve** the **cohesion** of the corneocytes. They are also believed to have an overall soothing effect and to exert a protective role against. . .

=>


L8 ANSWER 2 OF 2 USPATFULL on STN
AN 2001:29129 USPATFULL
TI Use of potentilla erecta extract in the cosmetic and pharmaceutical
field
IN Bonte, Frederic, Orleans, France
Dumas, Marc, Orleans, France
Chaudagne, Catherine, Vitry-Aux-Loges, France
Meybeck, Alain, Courbevoie, France
PA LVMH Recherche, Paris, France (non-U.S. corporation)
PI US 6193975 B1 20010227
WO 9819664 19980514
AI US 1999-297679 19990506 (9)
WO 1997-FR1988 19971106
19990506 PCT 371 date
19990506 PCT 102(e) date
PRAI FR 1996-13585 19961107
DT Utility
FS Granted
LN.CNT 639
INCL INCLM: 424/195.100
NCL NCLM: 424/725.000
IC [7]
ICM: A61K035-78
EXF 424/195.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 8 USPATFULL on STN
AN 2001:29129 USPATFULL
TI Use of potentilla erecta extract in the cosmetic and pharmaceutical
field
IN Bonte, Frederic, Orleans, France
Dumas, Marc, Orleans, France
Chaudagne, Catherine, Vitry-Aux-Loges, France
Meybeck, Alain, Courbevoie, France
PA LVMH Recherche, Paris, France (non-U.S. corporation)
PI US 6193975 B1 20010227
WO 9819664 19980514
AI US 1999-297679 19990506 (9)
WO 1997-FR1988 19971106
19990506 PCT 371 date
19990506 PCT 102(e) date
PRAI FR 1996-13585 19961107
DT Utility
FS Granted
LN.CNT 639
INCL INCLM: 424/195.100
NCL NCLM: 424/725.000
IC [7]
ICM: A61K035-78
EXF 424/195.1
CAS INDEXING IS AVAILABLE FOR THIS




29 REFERENCES IN FILE CA (1967 TO DATE)
29 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 19 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 82744-08-9 REGISTRY
CN **1,1'-Bistannin, 1,1'-bis(acetyloxy)dodecahydro-** (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Bistannacyclohex-1-yl, 1,1'-bis(acetyloxy)-
CN Stannacyclohexane, bimol. deriv.
CN Stannin, bimol. deriv.
MF C14 H26 O4 Sn2
LC STN Files: CA, CAPLUS




1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 20 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 82744-07-8 REGISTRY
CN **1,1'-Bistannin, dodecahydro-1,1'-dihydroxy-** (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Bistannacyclohex-1-yl, 1,1'-dihydroxy-
CN Stannacyclohexane, bimol. deriv.
CN Stannin, bimol. deriv.
MF C10 H22 O2 Sn2
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 21 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 82744-05-6 REGISTRY
CN **1,1'-Bistannin, dodecahydro-1,1'-diphenyl-** (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Bistannacyclohex-1-yl, 1,1'-diphenyl-
CN Stannacyclohexane, bimol. deriv.
CN Stannin, bimol. deriv.
MF C22 H30 Sn2
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 22 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 68989-19-5 REGISTRY *
* Use of this CAS Registry Number alone as a search term in other STN files may

result in incomplete search results. For additional information, enter HELP
RN* at an online arrow prompt (=>).

CN **Antimony, C.I. Basic Violet 1 tannin complexes** (CA INDEX NAME)

OTHER NAMES:

CN **Antimony, methylated 4-[(4-aminophenyl)(4-imino-2,5-cyclohexadien-1-ylidene)methyl]benzenamine tannin complexes**

DEF The complex of antimony and tannins with the substance identified in the COLOUR INDEX by Colour Index Constitution Number, C.I. 42535.

MF Unspecified

CI MAN, GRS

LC STN Files: CHEMLIST

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 23 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 68957-23-3 REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files may

result in incomplete search results. For additional information, enter HELP
RN* at an online arrow prompt (=>).

CN **Antimony, 4-[(4-aminophenyl)(4-imino-2,5-cyclohexadien-1-ylidene)methyl]-2-methylbenzenamine tannin complexes** (CA INDEX NAME)

MF Unspecified

CI MAN, GRS

LC STN Files: CHEMLIST

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 24 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 68201-64-9 REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files may

result in incomplete search results. For additional information, enter HELP
RN* at an online arrow prompt (=>).

CN **Tannins, sulfomethylated** (CA INDEX NAME)

OTHER NAMES:

CN **Tannin, sulfomethylated**

MF Unspecified

CI MAN, CTS

LC STN Files: CHEMLIST

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 25 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 67373-85-7 REGISTRY

CN **1,1'-Bistannin, dodecahydro-1,1'-dimethyl-** (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Bistannacyclohex-1-yl, 1,1'-dimethyl-


CN Stannacyclohexane, bimol. deriv.

CN Stannin, bimol. deriv.

MF C12 H26 Sn2

LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT

(*File contains numerically searchable property data)



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)



L3 ANSWER 26 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 56646-19-6 REGISTRY
CN **SBS (tannin) (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN Syntan SBS
MF Unspecified
CI MAN
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 27 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 37064-30-5 REGISTRY
CN [4,8':4',8''-Ter-2H-1-benzopyran]-3,3',3'',5,5',5'',7,7',7''-nonol,
2,2',2''-tris(3,4-dihydroxyphenyl)-3,3',3'',4,4',4''-hexahydro-,
(2R,2'R,2''R,3R,3'R,3''R,4R,4'S) - (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN [4,8':4',8''-Ter-2H-1-benzopyran]-3,3',3'',5,5',5'',7,7',7''-nonol,
2,2',2''-tris(3,4-dihydroxyphenyl)-3,3',3'',4,4',4''-hexahydro-,
[2R-[2.alpha.,3.alpha.,4.beta.[2'R*,3'R*,4'S*(2''R*,3''R*)]]]-
OTHER NAMES:
CN **Cinnamtannin A1**
CN Proanthocyanidin C1
CN Procyanidin C1
CN Procyanidol C1
FS STEREOSEARCH
DR 65085-09-8
MF C45 H38 O18
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAPLUS, DDFU,
DRUGU, NAPRALERT, RTECS*, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

167 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

167 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 28 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 9025-71-2 REGISTRY

CN Tannase (9CI) (CA INDEX NAME)

OTHER NAMES:

CN E.C. 3.1.1.20

CN Tannase S

CN **Tannin acetylhydrolase**

CN **Tannin acylhydrolase**

CN Teazyme C

MF Unspecified

CI MAN

LC STN Files: AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA,

CAPLUS, CHEMCATS, CHEMLIST, CIN, CSCHEM, EMBASE, IFICDB, IFIPAT,
IFIUDB,

PROMT, TOXCENTER, USPATFULL

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

208 REFERENCES IN FILE CA (1967 TO DATE)

3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

208 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 29 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 9010-29-1 REGISTRY

CN Helgotan (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN **Tannin-formaldehyde**

CN Tannoform

MF Unspecified

CI PMS, MAN

PCT Manual registration

LC STN Files: AGRICOLA, BIOSIS, CHEMCATS, CHEMLIST, CIN, CSCHEM, MRCK*,
PIRA

(*File contains numerically searchable property data)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 30 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 9009-66-9 REGISTRY

CN Protan (8CI) (CA INDEX NAME)

OTHER NAMES:

CN **Tannin nucleoprotein**

MF Unspecified

CI PMS, MAN

PCT Manual registration

LC STN Files: BIOBUSINESS, BIOSIS, CIN, PROMT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 31 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 9006-52-4 REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files
may

result in incomplete search results. For additional information, enter HELP

RN* at an online arrow prompt (=>).

CN Tannins, albumin complexes (CA INDEX NAME)

OTHER NAMES:

CN Albumin tannate

CN Albutannin

CN Albutannins

CN Tannalbin

CN Tannalbins

CN **Tannin albuminate**

MF Unspecified

CI MAN, CTS

LC STN Files: ADISNEWS, ANABSTR, BIOTECHNO, CA, CAPLUS, CHEMCATS,
CHEMLIST,


CSCHEM, DDFU, DRUGU, EMBASE, IPA, USAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 32 OF 38 REGISTRY COPYRIGHT 2002 ACS
 RN 6837-45-2 REGISTRY
 CN Phenazinium,
 3-amino-7-(dimethylamino)-5-(2,4-dimethylphenyl)-1,4-dimethyl-
 , chloride (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Phenazinium, 3-amino-7-(dimethylamino)-1,4-dimethyl-5-(2,4-xylyl)-,
 chloride (8CI)
 CN **Tannin Heliotrope** (6CI)
 OTHER NAMES:
 CN C.I. 50260
 CN Girofle
 MF C24 H27 N4 . Cl
 LC STN Files: CAOLD, CHEMLIST
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (119192-43-7)




● Cl⁻

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


L3 ANSWER 33 OF 38 REGISTRY COPYRIGHT 2002 ACS
 RN 5424-20-4 REGISTRY
 CN .beta.-D-Glucopyranose, pentakis[3,4-dihydroxy-5-[(3,4,5-trihydroxybenzoyl)oxy]benzoate] (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN **Chinese gallotannin**
 CN Pentadigalloylglucose
 FS STEREOSEARCH
 DR 88196-66-1, 42804-73-9
 MF C76 H52 O46
 LC STN Files: BIOBUSINESS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST,
 NIOSHTIC, USPATFULL
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



```

L3      ANSWER 34 OF 38      REGISTRY    COPYRIGHT 2002 ACS
RN      1482-79-7    REGISTRY
CN      2-Naphthalenol, 1-[[4-[(diethylamino)methyl]phenyl]azo]- (9CI)    (CA INDEX
NAME)
OTHER CA INDEX NAMES:
CN      2-Naphthol, 1-[[.alpha.-(diethylamino)-p-tolyl]azo]- (8CI)
OTHER NAMES:
CN      C.I. 12130
CN      Tannin Orange R
FS      3D CONCORD
MF      C21 H23 N3 O
LC      STN Files:    BEILSTEIN*, CA, CAPLUS
          (*File contains numerically searchable property data)

```



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 35 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 1407-83-6 REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files may

result in incomplete search results. For additional information, enter HELP
RN* at an online arrow prompt (=>).

CN **Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, tannin complexes**
(CA INDEX NAME)

OTHER NAMES:

CN Quinine tannate

MF Unspecified

CI MAN, GRS

LC STN Files: BIOSIS, CHEMLIST, USAN

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 36 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 1406-48-0 REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files may

result in incomplete search results. For additional information, enter HELP
RN* at an online arrow prompt (=>).

CN Tannins, aluminum salts (CA INDEX NAME)

OTHER NAMES:

CN Aluminum tannates

CN **Aluminum tannin salts**

CN Tannal

CN Tannal insoluble

MF Unspecified

CI MAN, CTS

LC STN Files: CHEMCATS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 37 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 1401-55-4 REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files may

result in incomplete search results. For additional information, enter HELP
RN* at an online arrow prompt (=>).

CN Tannins (CA INDEX NAME)

OTHER NAMES:

CN AL

CN **AL (tannin)**

CN Brewtan

CN Catechins

CN **F-Tannin**

CN Floctan 1

CN Floctan 3

CN Fresh Shiraimatsu FS 500M

CN Gallotannic acids

CN Gallotannins

CN Hifix SL


CN Hifix SLA

CN MP-TR

CN Quertanil
 CN Resorcinex Pecan Tannin 9901L
 CN Sunlife TN
 CN Tanal 1
 CN Tanaphen P 500
 CN Tanex RS 93
 CN Tannic Acid X
 CN Tannic acids
 CN TW 75
 CN Vitanil B
 CN Vitanil IM
 CN Weibull
 DEF Gallic acid derivatives found in nutgalls, bark and other plant parts, especially oak bark.
 DR 93615-37-3, 67167-65-1, 61790-06-5, 73891-88-0
 MF Unspecified
 CI COM, MAN, CTS
 LC STN Files: AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, NAPRALERT, NIOSHTIC, RTECS*, TOXCENTER, USAN, USPATFULL, VTB
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 100 REFERENCES IN FILE CA (1967 TO DATE)
 100 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 38 OF 38 REGISTRY COPYRIGHT 2002 ACS
 RN 508-07-6 REGISTRY
 CN [4,4'-Bi-2H-1-benzopyran]-4,4',5,5',7,7'-hexol, 2,2'-bis(3,4-dihydroxyphenyl)-3,3',4,4'-tetrahydro- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN [4,4''-Biflavine]-3',3''',4,4',4'',4''',5,5'',7,7''-decol (8CI)
 OTHER NAMES:
 CN Hemlock tannin
 MF C30 H26 O12



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> d 1-7 ibib ab

L11 ANSWER 1 OF 7 USPATFULL

ACCESSION NUMBER: 2002:185305 USPATFULL
TITLE: USE OF ELLAGIC ACID AND ITS DERIVATIVES IN COSMETICS
AND DERMATOLOGY
INVENTOR(S): BONTE, FREDERIC, ORLEANS, FRANCE
SAUNOIS, ALEX, ORLEANS, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098213	A1	20020725
APPLICATION INFO.:	US 2000-508670	A1	20000328 (9)
	WO 1998-FR2098		19981001

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1997-12227	19971001
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DENNISON, SCHULTZ & DOUGHERTY, 1745 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	602	

AB The invention relates to the use of ellagic acid and its derivatives in the field of cosmetics and pharmacy, especially dermatology.

It relates more particularly to all applications where it is desired to reinforce the dermal-epidermal junction or improve hair condition by increasing the proportion of collagen VII in the presence of keratinocytes and/or fibroblasts.

In particular, these applications involve toning up the skin, reducing wrinkles or improving hair condition.

L11 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:738287 CAPLUS
DOCUMENT NUMBER: 135:293712
TITLE: Skin-lightening cosmetics containing chromanol
glycosides and other active agents
INVENTOR(S): Ishida, Misaki; Sato, Saori; Murase, Hironobu
PATENT ASSIGNEE(S): NOF Corporation, Japan; CCI Corp.
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001278774	A2	20011010	JP 2000-96833	20000331

OTHER SOURCE(S): MARPAT 135:293712

AB This invention relates to a skin-lightening cosmetic compn. comprising
(1) 0.001-20 % chromanol glycosides and (2) .gtoreq. 1 agent selected from
the group consisting of ascorbic acid, placenta exts., kojic acid,

ellagic acid, hydroquinone, retinol, tocopherol, glucosamine, azelaic acid, pyridoxine, cinnamic acid, and derivs. thereof. The compns. also moisturize the skin and provide anti-wrinkle effects. Chromanol glucosides were prepd. by treating 2-hydroxymethyl-2,5,7,8-tetramethylchroman-6-ol with dextrin in the presence of cyclomaltodextrin glucanotransferase. A cream contained chromanol monoglucoside 3, kojic acid 1, tocopherol acetate 0.05, cetanol 3, decamethylcyclopentasiloxane 3, Na sulfite 0.05, other additives q.s., and purified water balance to 100 %.

L11 ANSWER 3 OF 7 USPATFULL

ACCESSION NUMBER: 1998:150988 USPATFULL
 TITLE: Method of stimulating gastrointestinal motility with ellagic acid
 INVENTOR(S): Rajagopalan, Tuticorin Govindachari, Bombay, India
 Khambe, Deepa Ashok, Bombay, India
 PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843987		19981201
APPLICATION INFO.:	US 1997-999635		19971031 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-30421P	19961031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rose, Shep K.	
LEGAL REPRESENTATIVE:	Zea, Betty J., Howell, John M., Rasser, Jacobus C.	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	795	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of ellagic acid for the treatment of gastrointestinal disorders by stimulating the motility of the GI tract. In particular the present invention relates to a method of treatment of constipation, heartburn, non ulcer dyspepsia, GERD, and/or esophagitis, with a pharmaceutical composition comprising a safe and effective amount of ellagic acid or pharmaceutically acceptable salts or esters thereof. Preferably the ellagic acid is administered perorally.

L11 ANSWER 4 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1991:288495 BIOSIS
 DOCUMENT NUMBER: BR41:8915
 TITLE: LUNG TUMORIGENICITY OF NNK GIVEN ORALLY TO A-J MICE ITS APPLICATION TO CHEMOPREVENTIVE EFFICACY STUDIES.
 AUTHOR(S): CASTONGUAY A; PEPIN P; STONER G D
 CORPORATE SOURCE: LAB. CANCER ETIOL. CHEMOPREVENTION, SCH. PHARM., LAVAL UNIV., QUEBEC CITY, CAN. G1K 7P4.
 SOURCE: SYMPOSIUM ON MOUSE PULMONARY CARCINOGENESIS, RESEARCH TRIANGLE PARK, NORTH CAROLINA, USA, MARCH 27-28, 1990. EXP LUNG RES, (1991) 17 (2), 485-500.
 CODEN: EXLRDA. ISSN: 0190-2148.
 DOCUMENT TYPE: Conference
 FILE SEGMENT: BR; OLD
 LANGUAGE: English

L11 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
ACCESSION NUMBER: 1991:156762 CAPLUS
DOCUMENT NUMBER: 114:156762
TITLE: The effects of **ellagic acid** and
13-cis-**retinoic acid** on
N-nitrosobenzylmethylamine-induced esophageal
tumorigenesis in rats
AUTHOR(S): Daniel, E. M.; Stoner, G. D.
CORPORATE SOURCE: Dep. Pathol., Med. Coll. Ohio, Toledo, OH, 43699, USA
SOURCE: Cancer Lett. (Shannon, Irel.) (1991), 56(2), 117-24
CODEN: CALEDQ; ISSN: 0304-3835
DOCUMENT TYPE: Journal
LANGUAGE: English

AB **Ellagic acid** (EA) and 13-cis-**retinoic acid** (CRA), alone and in combination, were tested for their ability to inhibit N-nitrosobenzylmethylamine-induced tumors in the rat esophagus. Male rats were fed EA (4 g/kg), CRA (240 mg/kg), or a combination of EA and CRA (4 g/kg and 240 mg/kg) for 25 wk. NBMA (0.5 mg/kg per injection) was administered s.c. once a week for 15 wk starting in the 3rd wk. After 25 wk, the incidence of esophageal tumors was 97-100% in NBMA-treated rats. The multiplicity of tumors in NBMA-treated rats was reduced by EA (60%), but not by CRA or by EA + CRA. Thus, EA and
CRA do not act synergistically to inhibit NBMA-induced esophageal tumorigenesis.

L11 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1991:448123 CAPLUS
DOCUMENT NUMBER: 115:48123
TITLE: Quantitation and liberation of **ellagic acid** in dietary sources, and its effects, in combination with 13-cis-**retinoic acid**, on the development of N-nitrosobenzylmethylamine-induced esophageal tumors in F344 rats
AUTHOR(S): Daniel, Elaine Marie
CORPORATE SOURCE: Med. Coll. Ohio, OH, USA
SOURCE: (1990) 161 pp. Avail.: Univ. Microfilms Int., Order No. DA9107345
From: Diss. Abstr. Int. B 1991, 51(10), 4787
DOCUMENT TYPE: Dissertation
LANGUAGE: English
AB Unavailable

L11 ANSWER 7 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1990:325915 BIOSIS
DOCUMENT NUMBER: BR39:33251
TITLE: THE EFFECTS OF **ELLAGIC ACID** AND 13-CIS **RETINOIC ACID** ALONE AND IN COMBINATION ON N NITROSOBENZYL METHYLAMINE-INDUCED ESOPHAGEAL TUMORS IN RATS.
AUTHOR(S): DANIEL E; STONER G
CORPORATE SOURCE: MED. COLL. OHIO, TOLEDO, OHIO 43699, USA.
SOURCE: 81ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, WASHINGTON, D.C., USA, MAY 23-26, 1990. PROC AM ASSOC CANCER RES ANNU MEET, (1990) 31 (0), 120.
CODEN: PAMREA.
DOCUMENT TYPE: Conference
FILE SEGMENT: BR; OLD

L13 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:706945 CAPLUS
DOCUMENT NUMBER: 133:271409
TITLE: Cosmetic or dermatological compositions containing a substance for increasing the functionality and/or expression of CD44 membrane receptors of skin cells
INVENTOR(S): Dumas, Marc; Bonte, Frederic
PATENT ASSIGNEE(S): Parfums Christian Dior, Fr.
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000057836	A2	20001005	WO 2000-FR764	20000327
WO 2000057836	A3	20010517		
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2791260	A1	20000929	FR 1999-3840	19990326
EP 1165035	A2	20020102	EP 2000-915224	20000327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			FR 1999-3840	A 19990326
			WO 2000-FR764	W 20000327

L13 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:783901 CAPLUS
DOCUMENT NUMBER: 132:26672
TITLE: Antiaging cosmetic composition containing a salt or a divalent metal complex
INVENTOR(S): Bonte, Frederic; Dumas, Marc; Heusele, Catherine; Le Blay, Jacques
PATENT ASSIGNEE(S): Guerlain S.A., Fr.; Le Blay, Jacques
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962481	A1	19991209	WO 1999-FR1261	19990528
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2779059	A1	19991203	FR 1998-6822	19980529
EP 1082098	A1	20010314	EP 1999-922237	19990528
R: CH, DE, ES, FR, GB, IT, LI				
JP 2002516838	T2	20020611	JP 2000-551738	19990528
PRIORITY APPLN. INFO.:			FR 1998-6822	A 19980529
			US 1999-297679	A2 19990506
			WO 1999-FR1261	W 19990528

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L13 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:233777 CAPLUS

DOCUMENT NUMBER: 130:271881

TITLE: Antiaging cosmetic compositions containing
ellagic acid and its derivatives

INVENTOR(S): Bonte, Frederic; Saunois, Alex

PATENT ASSIGNEE(S): LVMH Recherche, Fr.

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9916415	A1	19990408	WO 1998-FR2098	19981001
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2768927	A1	19990402	FR 1997-12227	19971001
FR 2768927	B1	20000121		
EP 1021161	A1	20000726	EP 1998-946538	19981001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001517688	T2	20011009	JP 2000-513553	19981001
US 2002098213	A1	20020725	US 2000-508670	20000328
PRIORITY APPLN. INFO.:			FR 1997-12227	A 19971001
			WO 1998-FR2098	W 19981001
REFERENCE COUNT:	7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE		

FORMAT

L13 ANSWER 4 OF 5 USPATFULL

ACCESSION NUMBER: 2002:185305 USPATFULL

TITLE: USE OF **ELLAGIC ACID** AND ITS
DERIVATIVES IN COSMETICS AND DERMATOLOGY

INVENTOR(S): BONTE, FREDERIC, ORLEANS, FRANCE

SAUNOIS, ALEX, ORLEANS, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098213	A1	20020725
APPLICATION INFO.:	US 2000-508670	A1	20000328 (9)
	WO 1998-FR2098		19981001

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1997-12227	19971001
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DENNISON, SCHULTZ & DOUGHERTY, 1745 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	602	

L13 ANSWER 5 OF 5 USPATFULL

ACCESSION NUMBER: 2001:29129 USPATFULL

TITLE: Use of potentilla erecta extract in the cosmetic and pharmaceutical field

INVENTOR(S): Bonte, Frederic, Orleans, France
Dumas, Marc, Orleans, France
Chaudagne, Catherine, Vitry-Aux-Loges, France
Meybeck, Alain, Courbevoie, France

PATENT ASSIGNEE(S): LVMH Recherche, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6193975	B1	20010227
	WO 9819664		19980514
APPLICATION INFO.:	US 1999-297679		19990506 (9)
	WO 1997-FR1988		19971106
			19990506 PCT 371 date
			19990506 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1996-13585	19961107
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Prats, Francisco	
ASSISTANT EXAMINER:	Coe, Susan D.	
LEGAL REPRESENTATIVE:	Nath & Associates, Nath, Gary M.	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	639	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 476-66-4 REGISTRY
CN [1]Benzopyrano[5,4,3-cde][1]benzopyran-5,10-dione, 2,3,7,8-tetrahydroxy-
(7CI, 8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN Alizarin yellow
CN Alizarine Yellow
CN Benzoaric acid
CN C.I. 55005
CN C.I. 75270
CN Elagostasine
CN Eleagic acid
CN **Ellagic acid**
CN Gallogen
CN Gallogen (astringent)
CN Lagistase
CN [1,1'-Biphenyl]-2,2'-dicarboxylic acid, 4,4',5,5',6,6'-hexahydroxy-,
di-.delta.-lactone
FS 3D CONCORD
DR 124590-32-5, 77415-21-5
MF C14 H6 O8
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU,
EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT,
NIOSTIC, PHAR, PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN,


USPAT2,

USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1184 REFERENCES IN FILE CA (1967 TO DATE)


51 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1186 REFERENCES IN FILE CAPLUS (1967 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

SPATFULL

(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1184 REFERENCES IN FILE CA (1967 TO DATE)
51 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1186 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s tannin/cn
L2 0 TANNIN/CN

=> s tannin
L3 38 TANNIN

=> s tannic acid/cn
L4 0 TANNIC ACID/CN

=> d l3 1-38

L3 ANSWER 1 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 438544-88-8 REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files may

result in incomplete search results. For additional information, enter HELP

RN* at an online arrow prompt (=>).

CN Tannins, phlorotannins (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Tannins, phloro-

OTHER NAMES:

CN Gallotannic acids, phloro-

CN Gallotannins, phloro-

CN Phenalgin

CN **Phenalgin (phlorotannin)**

CN Phlorotannins

CN Tannic acids, phloro-

MF Unspecified

CI MAN, CTS

SR CA

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 2 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 438544-84-4 REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files may

result in incomplete search results. For additional information, enter HELP

RN* at an online arrow prompt (=>).

CN Tannins, ellagitannins (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Tannins, ellagi-

OTHER NAMES:

CN Ellagigallotannic acids

CN Ellagigallotannins

CN Ellagitannic acids

CN Ellagitannins

CN Gallotannic acids, ellagi-

CN Gallotannins, ellagi-

CN Oenotan

CN SH 10L

CN Tannic acids, ellagi-

CN **Tannin, ellagitannins**

MF Unspecified

CI MAN, CTS

SR CA

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 3 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 208659-30-7 REGISTRY

CN Benzo[1,2-b:3,4-b']bis[1,4]benzodioxin-1,3,6,10,12-pentol (9CI) (CA INDEX

NAME)

OTHER NAMES:


CN **Phlorotannin A**

FS 3D CONCORD

MF C18 H10 O9

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 4 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 166833-80-3 REGISTRY

CN .beta.-D-Glucopyranose, 1-(3,4,5-trihydroxybenzoate), cyclic

2.fwdarw.2:4.fwdarw.1-ester with

(5-carboxy-3,4-dihydro-3,7,8-trihydroxy-2-

oxo-2H-1-benzopyran-4-yl)butanedioic acid, [3S-[3.alpha.,4.alpha.(R*)]]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN Chebulanin
CN Terminalic acid
CN **Terminalic acid (tannin)**
MF C27 H24 O19
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

5 REFERENCES IN FILE CA (1967 TO DATE)

5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 5 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 140145-40-0 REGISTRY

CN 8,14-Methano-2H,14H-1-benzopyrano[7,8-d][1,3]benzodioxocin-3,5,11,13,15-pentol, 2,8-bis[3,4-bis(acetyloxy)phenyl]-3,4-dihydro-4-[3,5,7-


tris(acetyloxy)-2-[3,4-bis(acetyloxy)phenyl]-3,4-dihydro-2H-1-benzopyran-8-yl]-, pentaacetate,


[2R-[2.alpha.,3.alpha.,4.beta.(2R*,3R*),8.beta.,14.beta.a.,15R*]]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN **Cinnamtannin B1 peracetate**
MF C73 H64 O32
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 6 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 135116-96-0 REGISTRY
CN **RG tannin (9CI)** (CA INDEX NAME)
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 7 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 129737-10-6 REGISTRY
CN **Oxidase, tannin (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN Tannic acid oxidase
CN **Tannin oxidase**
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 8 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 97233-47-1 REGISTRY
CN 8,14-Methano-2H,14H-1-benzopyrano[7,8-d][1,3]benzodioxocin-3,5,11,13,15-pentol, 2,8-bis(3,4-dihydroxyphenyl)-10-[(2R,3R,4R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-3,5,7-trihydroxy-2H-1-benzopyran-4-yl]-4-[(2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-3,5,7-trihydroxy-2H-1-benzopyran-8-yl]-3,4-dihydro-, (2R,3R,4S,8R,14R,15R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 8,14-Methano-2H,14H-1-benzopyrano[7,8-d][1,3]benzodioxocin-3,5,11,13,15-pentol, 2,8-bis(3,4-dihydroxyphenyl)-10-[2-(3,4-dihydroxyphenyl)-3,4-


dihydro-3,5,7-trihydroxy-2H-1-benzopyran-4-yl]-4-[2-(3,4-dihydroxyphenyl)-3,4-dihydro-3,5,7-trihydroxy-2H-1-benzopyran-8-yl]-3,4-dihydro-,

[2R-[2.alpha.,3.alpha.,4.beta.(2R*,3S*),8.beta.,10(2R*,3R*,4R*),14.beta.,1


5R*]]-
 OTHER NAMES:
 CN **Cinnamtannin D2**
 FS STEREOSEARCH
 MF C60 H48 O24
 LC STN Files: BEILSTEIN*, CA, CAPLUS, NAPRALERT
 (*File contains numerically searchable property data)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 9 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 97233-06-2 REGISTRY
CN 8,14-Methano-2H,14H-1-benzopyrano[7,8-d][1,3]benzodioxocin-3,5,11,13,15-pentol, 2,8-bis(3,4-dihydroxyphenyl)-4-[(2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-3,5,7-trihydroxy-2H-1-benzopyran-8-yl]-3,4-dihydro-, (2R,3R,4S,,8S,14R,15R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 8,14-Methano-2H,14H-1-benzopyrano[7,8-d][1,3]benzodioxocin-3,5,11,13,15-pentol, 2,8-bis(3,4-dihydroxyphenyl)-4-[2-(3,4-dihydroxyphenyl)-3,4-dihydro-3,5,7-trihydroxy-2H-1-benzopyran-8-yl]-3,4-dihydro-, [2R-[2.alpha.,3.alpha.,4.beta.(2R*,3S*),8.beta.,14.beta.,15R*]]-

OTHER NAMES:

CN **Cinnamtannin D1**


FS STEREOSEARCH

MF C45 H36 O18

LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, NAPRALERT
(*File contains numerically searchable property data)



Absolute stereochemistry.


PAGE 1-A



4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1967 TO DATE)

6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 11 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 88082-60-4 REGISTRY

CN 8,14-Methano-2H,14H-1-benzopyrano[7,8-d][1,3]benzodioxocin-3,5,11,13,15-pentol, 2,8-bis(3,4-dihydroxyphenyl)-4-[(2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-3,5,7-trihydroxy-2H-1-benzopyran-8-yl]-3,4-dihydro-, (2R,3R,4S,8S,14R,15R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 8,14-Methano-2H,14H-1-benzopyrano[7,8-d][1,3]benzodioxocin-3,5,11,13,15-pentol, 2,8-bis(3,4-dihydroxyphenyl)-4-[2-(3,4-dihydroxyphenyl)-3,4-dihydro-3,5,7-trihydroxy-2H-1-benzopyran-8-yl]-3,4-dihydro-, [2R-[2.alpha.,3.alpha.,4.beta.(2R*,3R*),8.beta.,14.beta.,15R*]]-

OTHER NAMES:

CN **Cinnamtannin B1**



FS STEREOSEARCH

DR 86588-96-7

MF C45 H36 O18

LC STN Files: BEILSTEIN*, BIOBUSINESS, CA, CAPLUS, DDFU, DRUGU, TOXCENTER
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

22 REFERENCES IN FILE CA (1967 TO DATE)

22 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 12 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 88038-12-4 REGISTRY

CN 8,14-Methano-2H,14H-1-benzopyrano[7,8-d][1,3]benzodioxocin-3,5,11,13,15-pentol, 2,8-bis(3,4-dihydroxyphenyl)-10-[(2R,3R,4R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-3,5,7-trihydroxy-2H-1-benzopyran-4-yl]-4-[(2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-3,5,7-trihydroxy-2H-1-benzopyran-8-yl]-3,4-dihydro-, (2R,3R,4S,8R,14R,15R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN 8,14-Methano-2H,14H-1-benzopyrano[7,8-d][1,3]benzodioxocin-3,5,11,13,15-pentol, 2,8-bis(3,4-dihydroxyphenyl)-10-[2-(3,4-dihydroxyphenyl)-3,4-

dihydro-3,5,7-trihydroxy-2H-1-benzopyran-4-yl]-4-[2-(3,4-dihydroxyphenyl)-


3,4-dihydro-3,5,7-trihydroxy-2H-1-benzopyran-8-yl]-3,4-dihydro-,
 [2R-[2.alpha.,3.alpha.,4.beta.(2R*,3R*),8.beta.,10(2R*,3R*,4R*),14.beta.,1
 5R*]]-
 OTHER NAMES:
 CN **Cinnamtannin B2**
 FS STEREOSEARCH
 MF C60 H48 O24
 LC STN Files: AGRICOLA, BEILSTEIN*, CA, CAPLUS, DDFU, DRUGU, TOXCENTER
 (*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

14 REFERENCES IN FILE CA (1967 TO DATE)

14 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 13 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 86631-39-2 REGISTRY

CN [4,8':4',8'':4'',8''':4''',8''''-Quinque-2H-1-benzopyran] -
3,3',3'',3''',3''''-5,5',5'',5''',5''''-7,7',7'',7''',7''''-pentadecol,
2,2',2'',2''',2''''-pentakis(3,4-dihydroxyphenyl) -
3,3',3'',3''',3''''-4,4',4'',4''',4''''-decahydro-,
(2R,2'R,2''R,2'''R,2''''R,3R,3'R,3''R,3'''R,3''''R,4R,4'R,4''R,4'''S) -
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN [4,8':4',8'':4'',8''':4''',8''''-Quinque-2H-1-benzopyran] -
3,3',3'',3''',3''''-5,5',5'',5''',5''''-7,7',7'',7''',7''''-pentadecol,
2,2',2'',2''',2''''-pentakis(3,4-dihydroxyphenyl) -
3,3',3'',3''',3''''-4,4',4'',4''',4''''-decahydro-, [2R-
[2.alpha.,3.alpha.,4.beta.[2'R*,3'R*,4'R*[2''R*,3''R*,4''R*[2'''R*,
3'''R*,4'''S*(2''''R*,3''''R*)]]]]]] -

OTHER NAMES:

CN Cinnamtannin A3

CN Cinnamtannin II


FS STEREOSEARCH


MF C75 H62 O30

LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 REFERENCES IN FILE CA (1967 TO DATE)

9 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 14 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 86631-38-1 REGISTRY

CN [4,8':4',8'':4'',8'''-Quater-2H-1-benzopyran]-
3,3',3'',3''',5,5',5'',5'''-dodecol, 2,2',2'',2'''-
tetrakis(3,4-dihydroxyphenyl)-3,3',3'',3''',4,4',4'',4'''-octahydro-,
(2R,2'R,2''R,2'''R,3R,3'R,3''R,3'''R,4R,4'R,4''S)-(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN [4,8':4',8'':4'',8'''-Quater-2H-1-benzopyran]-
3,3',3'',3''',5,5',5'',5'''-dodecol, 2,2',2'',2'''-
tetrakis(3,4-dihydroxyphenyl)-3,3',3'',3''',4,4',4'',4'''-octahydro-,
stereoisomer

OTHER NAMES:

CN Cinnamtannin A2

CN Cinnamtannin I

FS STEREOSEARCH

DR 158112-57-3


MF C60 H50 O24

LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL


(*File contains numerically searchable property data)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

26 REFERENCES IN FILE CA (1967 TO DATE)

26 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 15 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 84777-04-8 REGISTRY *

* Use of this CAS Registry Number alone as a search term in other STN files may

result in incomplete search results. For additional information, enter HELP
RN* at an online arrow prompt (=>).

CN **Antimony, N-[4-[4-(diethylamino)phenyl][4-(ethylamino)-1-naphthalenyl]methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium tannin complexes** (CA INDEX NAME)

MF Unspecified

CI MAN, GRS

SR Commission of European Communities

LC STN Files: CHEMLIST

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L3 ANSWER 16 OF 38 REGISTRY COPYRIGHT 2002 ACS

RN 84744-50-3 REGISTRY

CN .beta.-D-Glucopyranose, cyclic 4.fwdarw.2':6.fwdarw.2-[(1S)-4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate] cyclic

2,3-[(1S)-4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate] 1-(3,4,5-trihydroxybenzoate) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN .beta.-D-Glucopyranose, cyclic

4.fwdarw.2':6.fwdarw.2-[4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate] cyclic

2,3-(4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate) 1-(3,4,5-trihydroxybenzoate), [2(S),4(S)]-

CN Dibenzo[g,i]dibenzo[6',7':8',9'] [1,4]dioxecino[2',3':4,5]pyrano[3,2-b] [1,5]dioxacycloundecin, .beta.-D-glucopyranose deriv.

OTHER NAMES:


CN Rugosin C

CN **Rugosin C (tannin)**

MF C48 H32 O31

LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, NAPRALERT, TOXCENTER

(*File contains numerically searchable property data)



— OH

— OH

HO OH


18 REFERENCES IN FILE CA (1967 TO DATE)
18 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 17 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 84744-49-0 REGISTRY
CN D-Glucose, cyclic 4.fwdarw.2':6.fwdarw.2-[(1S)-4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate] 2,3-bis(3,4,5-trihydroxybenzoate) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:

CN 7H-Dibenzo[g,i][1,5]dioxacycloundecin, D-glucose deriv.
CN D-Glucose, cyclic 4.fwdarw.2':6.fwdarw.2-[4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate] 2,3-bis(3,4,5-trihydroxybenzoate), (S)-

OTHER NAMES:

CN Rugosin B
CN **Rugosin B (tannin)**
MF C41 H30 O27
LC STN Files: BIOBUSINESS, BIOSIS, CA, CAPLUS, NAPRALERT



15 REFERENCES IN FILE CA (1967 TO DATE)
15 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L3 ANSWER 18 OF 38 REGISTRY COPYRIGHT 2002 ACS
RN 84744-48-9 REGISTRY
CN .beta.-D-Glucopyranose, cyclic 4.fwdarw.2':6.fwdarw.2-[(1S)-4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate] 1,2,3-tris(3,4,5-trihydroxybenzoate) (9CI) (CA INDEX

NAME)

OTHER CA INDEX NAMES:

CN .beta.-D-Glucopyranose, cyclic
4.fwdarw.2':6.fwdarw.2-[4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate] 1,2,3-tris(3,4,5-trihydroxybenzoate), (S)-
CN Dibenzo[g,i]pyrano[3,2-b][1,5]dioxacycloundecin, .beta.-D-glucopyranose deriv.

OTHER NAMES:

CN Rugosin A
CN **Rugosin A (tannin)**
MF C48 H34 O31
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, DDFU, DRUGU, MEDLINE, NAPRALERT, TOXCENTER
(*File contains numerically searchable property data)